New LaunchMay 19, 2026, 07:01 AM
Korro Bio Adds KRRO-111 for AATD to Pipeline with Strong Preclinical Data
AI Summary
Korro Bio announced the addition of KRRO-111 to its pipeline for the potential treatment of Alpha-1 Antitrypsin Deficiency (AATD). Preclinical data showed KRRO-111 achieved over 90% editing of the SERPINA1 transcript, resulting in approximately 90% repaired functional AAT protein in plasma and a near elimination of active Z-protein production in a mouse model. This positions KRRO-111 as a potential best-in-class candidate, leveraging the company's OPERA platform to address the root cause of AATD. Korro Bio is well-capitalized to advance KRRO-111 and KRRO-121 into clinical trials.
Key Highlights
- Korro Bio adds KRRO-111 to pipeline for Alpha-1 Antitrypsin Deficiency (AATD).
- KRRO-111 demonstrated >90% editing of SERPINA1 transcript in vivo.
- Achieved ~90% repaired functional AAT protein in plasma in mouse model.
- Nearly eliminated active Z-protein production, reducing it by ~95%.
- Showed progressive clearance of pre-existing aggregates, reduced by ~69% at day 28.
- KRRO-111 is a potential best-in-class therapeutic delivered subcutaneously.
- Company is well-capitalized to advance KRRO-111 and KRRO-121 into clinic.
Price Impact
More from KRRO